Patent intelligence · US
US 8252767
Substituted 4-{3-[6-amino-9-(3, 4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
Substituted 4-{3-[6-amino-9-(3, 4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR a…
Patent details — US 8252767
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 28, 2012
- Expiration
- Aug 23, 2032
- Applicant
- Dogwood Pharmaceuticals, Inc.
- Claims
- 25
- CPC classes
- A61K, A61K49/0002, A61K49/0004, A61P
Quick answer
US 8252767 (Substituted 4-{3-[6-amino-9-(3, 4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists) is held by Dogwood Pharmaceuticals, Inc.. Status: granted. Granted Aug 28, 2012. Expires Aug 23, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Dogwood Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 25
- CPC classes
- A61K, A61K49/0002, A61K49/0004, A61P, A61P1/00, A61P1/08
More from Dogwood Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 9446021
Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof
granted -
US 9120754
Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof
granted -
US 8349848
Pyrrolo[3,2-D]pyrimidines that are selective antagonists of A2B adenosine receptors
granted -
US 8293720
Substituted 4-{3-[6-amino-9-(3, 4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
granted -
US 8263762
Alkoxy-carbonyl-amino-alkynyl-adenosine compounds and derivatives thereof as A2AR agonists
granted -
US 8258142
Substituted 8-[6-amino-3-pyridyl]xanthines
granted
Frequently asked questions
What is US patent 8252767?
US 8252767 (Substituted 4-{3-[6-amino-9-(3, 4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists) is held by Dogwood Pharmaceuticals, Inc.. Status: granted. Granted Aug 28, 2012. Expires Aug 23, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8252767?
Dogwood Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.
When does US 8252767 expire?
Our index shows an expiration date of Aug 23, 2032 (6 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.